Stryker completes sale of U.S. spinal implants business

Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC.

“The sale of our spinal implants business enhances our strategic focus, positioning us to meet evolving customer needs and invest where we see the greatest opportunity for innovation and long-term growth,” said Kevin Lobo, Chair and CEO, Stryker. “We remain committed to the spine space through our Interventional Spine, Neurotechnology and Enabling Technologies businesses, as well as our strategic partnership with VB Spine. We’re grateful to our Spine team members for their contributions and confident they’re well positioned for continued success.”

VB Spine will have exclusive access to Mako Spine and Copilot for use with its implants in spine procedures.

Certain international markets are expected to transfer to VB Spine at later dates, subject to the completion of all legal and regulatory requirements and required consultations with employees and/or employee representatives.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or [email protected]

For media inquiries:
Kim Montagnino, Chief Communications Officer at 269-385-2600 or [email protected] 

You May Also Be Interested In

• Christopher DiGirolamo Named to The Best Lawyers in America 2027 Edition for Personal Injury Litigation
• Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
• Kimbell Royalty Partners Closes $221.2 Million Drop Down Acquisition